x.com/cremieuxrecueil/status/2108675806851412439
2 corrections found
a healthy, *normal length* lifetime.
Trikafta has improved cystic fibrosis outcomes dramatically, but evidence does not show that it gives CF patients a normal life expectancy. The latest Cystic Fibrosis Foundation survival estimate is 66 years, well below overall U.S. life expectancy.
Full reasoning
This overstates what is currently known about Trikafta.
The Cystic Fibrosis Foundation's own survival page says that, based on 2025 Registry data, the predicted median age of survival for people with CF born between 2021 and 2025 is 66 years. That is a major improvement, but it is not a normal U.S. lifespan. The same page also says that the Foundation still has "a long way to go" and notes that half of the deaths reported in the Registry in 2024 occurred before age 38.8.
For comparison, CDC FastStats reports U.S. life expectancy at birth is 79.0 years overall. So the best current CF survival estimate remains materially below the general-population norm.
The broader Cystic Fibrosis Foundation white paper also states that there is no cure for CF, that it remains a life-shortening disease, and that CFTR modulators such as Trikafta are not a cure and do not reverse existing lung damage.
So while Trikafta is a transformative therapy, saying it gives CF patients "a healthy, normal length lifetime" goes beyond the available evidence and conflicts with current CFF and CDC data.
3 sources
- Understanding Changes in Life Expectancy | Cystic Fibrosis Foundation
Based on 2025 Registry data, the median age of survival for people with CF who were born between 2021 and 2025 is predicted to be 66 years... half of the deaths reported in the Registry in 2024... occurred before the age of 38.8.
- FastStats - Life Expectancy | CDC
Life expectancy at birth ... Both sexes: 79.0 years ... Males: 76.5 years ... Females: 81.4 years.
- CF Foundation Payer-Provider Collaboration Best Practices White Paper
There is no cure for CF. It is a life-shortening disease... While these treatments address the underlying cause of the disease, they are not a cure. They also do not reverse existing lung damage.
makes cystic fibrosis patients vomit up mucus for about a week.
A short-lived increase in sputum after starting CFTR modulators is reported in some patients, but it is not a universal, established effect of Trikafta, and official standards describe it as "sputum purging," not vomiting.
Full reasoning
This claim overgeneralizes a variable patient experience into something Trikafta broadly "makes cystic fibrosis patients" do.
An international standards paper on CFTR modulator therapy says "Some individuals experience a period of 'sputum purging'" after starting treatment. That directly contradicts the post's blanket wording about cystic fibrosis patients as a class. The same standards describe this as a transient phenomenon in some people, not a universal one-week reaction.
In addition, the FDA prescribing information for Trikafta does not describe "vomiting up mucus" as a common adverse reaction. The labeled common adverse reactions are headache, upper respiratory tract infection, abdominal pain, diarrhea, rash, elevated liver enzymes, nasal congestion, and related effects. That does not prove no patient ever has a purge-like experience, but it does show this is not an established, universal effect of the drug.
A qualitative study of ETI (elexacaftor/tezacaftor/ivacaftor) experiences likewise reported that most participants noticed an initial increase in sputum expectoration in the first days to week after starting therapy—again, not all patients, and described as increased expectoration rather than vomiting.
So the evidence supports a narrower statement such as: some people report a temporary increase in sputum/coughing after starting Trikafta. The post's categorical claim is too broad and misstates the phenomenon.
3 sources
- Standards of care for CFTR variant-specific therapy (including modulators) for people with cystic fibrosis
Some individuals experience a period of “sputum purging” following VST commencement [59]. ... Outpatient review or an inpatient stay may be considered ... before and during this purge phase.
- TRIKAFTA Highlights of Prescribing Information
The most common adverse drug reactions to TRIKAFTA (≥5% of patients and at a frequency higher than placebo by ≥1%) were headache, upper respiratory tract infection, abdominal pain, diarrhea, rash, alanine aminotransferase increased, nasal congestion, blood creatine phosphokinase increased, aspartate aminotransferase increased, rhinorrhea, rhinitis, influenza, sinusitis, blood bilirubin increased and constipation.
- “An Amazing Transformation!” The Lived Experiences of Elexacaftor/Tezacaftor/Ivacaftor in Adults with Cystic Fibrosis
Most participants reported an initial increase in sputum expectoration within the first couple of days to a week after initiation (i.e., “the purge”).